Loading companies…

Proteomics International LaboratoriesLtd ASX:PIQ

0 opened or increased0 held1 reduced or exitedlatest position by manager, past 12 months90 days: 0 increased, 0 reduced. 1 managers in total.

Position history by manager 1 managersSelect a point to see the comment

Opened or increasedHeldReduced or exited Start or end of the position not reported

2026

31 Dec 2025 to today

Commentary 2 comments

DateManagerActionSummary

31 May 2026NorthStar Impact FundsExitNorthStar Impact Funds exited its position in Proteomics International Laboratories during May.

Monthly Report, price recorded $0.14

The source document link is a Pro feature

31 Dec 2025NorthStar Impact FundsHeldNorthStar Impact Funds continues to hold Proteomics International Laboratories because the company published two studies during December 2025, including a peer-reviewed study in the Internal Medicine Journal demonstrating clinically meaningful predictive accuracy for diabetes-related chronic kidney disease in Aboriginal Australians, for whom the overall health burden is seven times greater than for non-Indigenous people. The fund also notes Proteomics announced US lab accreditation by the College of American Pathologists and secured a US patent for its test for the early diagnosis of oesophageal cancer.

Monthly Report, price recorded $0.66

The source document link is a Pro feature

First mention by manager

Price recorded at each manager's first comment

Price at first mentionThe share price recorded when each of 1 managers first commented on PIQ.

View Pro

About Proteomics International LaboratoriesLtd

Healthcare, Life Sciences Tools and Services

Proteomics International Laboratories (ASX:PIQ), a predictive diagnostics company, was exited by NorthStar Impact Funds. In May 2026, NorthStar reported it exited Proteomics during the month. In December 2025, NorthStar noted Proteomics published two studies, including a peer-reviewed study in the Internal Medicine Journal showing its diabetic kidney disease test has clinical utility. Proteomics International operates in the Healthcare sector within the Life Sciences Tools and Services industry, and Thesis Tracker has captured 2 comments from 1 fund manager, NorthStar Impact Funds. Founded in 2001 and headquartered in Perth, Proteomics International develops predictive diagnostic tests using protein biomarkers, including PromarkerD for diabetic kidney disease and tests for endometriosis and oesophageal cancer, and provides bioanalytical services, pursuing commercialisation and reimbursement in Australia, the US and other markets.

Market cap: $19m
Price to earnings: Loss-making
Return on equity: -155.7%
Dividend yield: 0.0%
Price to book: 3.41x
Net margin: -301.3%
52-week range: $0.10 to $0.86

Company figures as of 15 Oct 2026. For information only.

Questions

Who is investing in Proteomics International LaboratoriesLtd (ASX:PIQ)?

Fund managers including NorthStar Impact Funds have invested in Proteomics International LaboratoriesLtd (ASX:PIQ).

What opportunities or catalysts do fund managers highlight for Proteomics International LaboratoriesLtd?

NorthStar highlights peer-reviewed evidence of the clinical utility of Proteomics' PromarkerD test, supporting commercial adoption.

What are the key risks to the Proteomics International LaboratoriesLtd investment thesis, according to fund managers?

NorthStar exited the position, and commercial uptake and reimbursement of Proteomics' diagnostic tests remain uncertain.

What does Proteomics International LaboratoriesLtd (ASX:PIQ) do?

Proteomics International Laboratories Ltd. is an Australian medical technology company focused on predictive diagnostics and bio-analytical services. Founded in 2001 by Richard Lipscombe and Bill Parker, the company is headquartered in Perth, Australia. This company overview highlights its core business areas and background for investors reviewing company and fund manager commentary.

General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.

11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.

Disclaimer Terms of Use Privacy Complaints Contact

Loading…